These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 9102222)

  • 21. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
    Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
    Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific antibody production to a recall or a neoantigen by SCID mice reconstituted with human peripheral blood lymphocytes.
    Nonoyama S; Smith FO; Ochs HD
    J Immunol; 1993 Oct; 151(7):3894-901. PubMed ID: 8376809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of HPV16 positive cervical cancer model in the hu-PBL-SCID mouse and its immunological features].
    Liang ZX; Cheng Q; Chen HZ; Xie X; Ye DF
    Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1465-9. PubMed ID: 15500747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antitumor effect of gene therapy with recombinant adenovirus-mediated human interleukin-2 gene transfer and its mechanism].
    Du J; Ran Y; Lin Z; Zheng C; Wei H; Wang X; Zhou L; Ren Y
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):12-5. PubMed ID: 15600167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting p53 for adoptive T-cell immunotherapy.
    McCarty TM; Liu X; Sun JY; Peralta EA; Diamond DJ; Ellenhorn JD
    Cancer Res; 1998 Jun; 58(12):2601-5. PubMed ID: 9635585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12.
    Mazzolini G; Qian C; Xie X; Sun Y; Lasarte JJ; Drozdzik M; Prieto J
    Cancer Gene Ther; 1999; 6(6):514-22. PubMed ID: 10608348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
    Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
    Hess SD; Egilmez NK; Shiroko J; Bankert RB
    Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
    Somasundaram R; Jacob L; Swoboda R; Caputo L; Song H; Basak S; Monos D; Peritt D; Marincola F; Cai D; Birebent B; Bloome E; Kim J; Berencsi K; Mastrangelo M; Herlyn D
    Cancer Res; 2002 Sep; 62(18):5267-72. PubMed ID: 12234995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
    Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
    Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
    Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
    Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154.
    Loskog A; Tötterman TH; Böhle A; Brandau S
    Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deficient cytokine response of human allergen-specific T lymphocytes from humanized SCID mice and reconstitution by professional antigen-presenting cells.
    Jarman ER; Perschke K; Montermann E; Herz U; Renz H; Knop J; Reske-Kunz AB
    J Allergy Clin Immunol; 2000 May; 105(5):967-74. PubMed ID: 10808178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
    Wang L; Qi X; Sun Y; Liang L; Ju D
    Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.